methenolone

The average daily dose of 1 tablet 3 times daily (equivalent to 600 mg arbamazepina). In severe cases, the dose during the first days can be increased methenolone to two tablets three times a day (equivalent to 1200 mg of carbamazepine).

Trigeminal neuralgia, glossopharyngeal neuralgia genuinnaya.

The initial dose is 1 to 2 tablets (corresponding to 200 – 400 mg of carbamazepine), which up to the complete disappearance of pain increased to an average of 2 – 4 tablets (corresponding to 400 – 800 mg of carbamazepine) that distribute 1-2 daily administration. After that a certain part of the treatment of patients can continue to lower maintenance dose is 1 tablet 2 times a day (equivalent to 400 mg of carbamazepine).

Elderly patients and patients sensitive to karabamazepinu, finlepsin administered in an initial dose of 1/2 tablet
2 times a day (equivalent to 200 mg of carbamazepine).

Pain in diabetic neuropathy.

The average daily dose of 1 tablet 3 times daily (equivalent to 600 mg of carbamazepine). In exceptional cases finlepsin can be administered in a dose of 2 tablets 3 times a day (equivalent to 1200 mg of carbamazepine).

Epileptiform seizures in multiple sclerosis.

The average daily dose of 1 – 2 tablets 2 times per day (corresponding to 400 – 800 mg of carbamazepine).

Treatment and prevention of psychoses

The initial dose is typically sufficient, and also as a maintenance dose, is 1 – 2 tablets per day (corresponding to 200 – 400 mg of carbamazepine). If necessary, this dose may be increased to 2 tablets 2 times per day (corresponding to 800 mg of carbamazepine).

Duration of treatment depends on the indication and the patient’s individual response to the drug. epilepsy treatment is carried out for a long time. On methenolone the transfer of the patient to finlepsin, duration of application and cancel it in each case should be decided by a specialist doctor. The dose can be reduced or therapy discontinued no earlier than after 2 – 3 years of absence seizures.

Treatment stopped gradually decreasing doses for 1 – 2 years. In this case should be considered in children increase body weight.  Indicators should not be degraded.

In the treatment of neuralgia is the appointment of appropriate finlepsin at a dose sufficient to relieve pain, for several weeks. Lowering the dose necessary to investigate the possibility of the symptoms return. With the resumption of pain treatment continued to carry out maintenance dose.

The duration of treatment of pain associated with diabetic neuropathy and epileptiform spasms in multiple sclerosis is installed is the same as in neuralgia.

Treatment of alcohol withdrawal syndrome finlepsin stop tapering within 7 to 10 days.

 

Side effect:

When evaluating the frequency of occurrence of various adverse reactions following grading used: frequent (greater than 1 in 100 destinations), not frequent (less than 1 case per 100 prescriptions) and rare (less than 1 case per 1,000 appointments)

Of the central and peripheral nervous systems:

frequent – dizziness, ataxia, drowsiness, weakness, headache, paresis of accommodation;

not frequent – abnormal involuntary methenolone movements (eg tremor, “fluttering” tremor – asterixis, dystonia, tics); nystagmus;

rare – orofacial dyskinesia, oculomotor disturbances, speech disorders (eg dysarthria or slurred speech), horeoatetoidnye disorders, peripheral neuritis, paresthesia, muscle weakness and symptoms of paresis. The role of carbamazepine as the drug causes or contributes to the development of neuroleptic malignant syndrome, especially when it is administered in conjunction with neuroleptics, remains unclear.

From the psychic sphere:

rare – hallucinations (visual or auditory), depression, loss of appetite, restlessness, aggressive behavior, psycho-motor agitation, disorientation, activation of psychosis.